Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risks

Thorax

Volumn 51, Issue 4, 1996, Pages 364-368

  Mukhopadhyay, S ^a   Singh, M ^a   Cater, J I ^a   Ogston, S ^a   Franklin, M ^a   Olver, R E ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cystic fibrosis; Meta analysis; Nebulised antibiotics; Systematic review

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBENICILLIN; CEFTAZIDIME; COLISTIN; GENTAMICIN; TOBRAMYCIN;

ARTICLE; CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT;

EID: 0029877773     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.4.364     Document Type: Article

References (33)

1. Pitcher-Wilmott RW, Levinsky RJ, Gordon I, Turner MW, Mathew, DJ. Pseudomonas infection, allergy and cystic fibrosis. Arch Dis Child 1982;57:582-6.
2. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Lancet 1981;ii: 1137-9.
3. Stead RJ, Hodson ME, Batten JC. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987;81:273-9.
4. Jensen T, Pedersen SS, Garne S, Heilmann C, Hoiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-8.
5. Jenkins SG, Kelly WC, Mason WG, Peele JD, Cruse MA, Coludro EO, et al. Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. Presented at the 26th Meeting of the Cystic Fibrosis Foundation, Anaheim, California, 16-19 May, 1985 (abstract).
6. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
7. Steinkamp G, Tummler B, Gappa M, Albus A, Potel J, Doring G, et al. Long term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonal 1989;6:91-8.
8. Carswell F, Ward C, Cook DA, Speller DCE. A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the out patient management of children with cystic fibrosis. Br J Dis Chest 1987;81:356-60.
9. Kun P, Landau LI, Phelan PD. Nebulized gentamicin in children and adolescents with cystic fibrosis. Austr Pediatr J 1984;20:43-5.
10. Wall MA, Terry AB, Fisenberg J, McNamara M, Cohen R. Inhaled antibiotics in cystic fibrosis. Lancet 1983;i:1325.
11. Nathanson I, Kropp GJA, Li Philip, Neter E. Effectiveness of aerosolized gentamicin in cystic fibrosis (CF). Presented at the 26th meeting of the Cystic Fibrosis Foundation, Anaheim, California, 16-19 May, 1985 (abstract).
12. Wang C, Rolden MA, Aufderheide M, Sehgal SS. The effect of tobramycin aerosol on pulmonary infection from Pseudomonas aeroginosa in patients with cystic fibrosis (CF). Presented at the 25th Annual Meeting of the Cystic Fibrosis Foundation, San Jose, California, 27-30 April, 1984 (abstract).
13. Maclusky IB, Gold R, Corey M, Levison H. Long term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonal 1989;7:42-8.
14. Franz MN, Spohn WA, Ronald PM. Evaluation of aerosol tobramycin therapy in CF. Presented at the 26th Annual Meeting of the Cystic Fibrosis Foundation, Anaheim, California, 16-19 May, 1985 (abstract).
15. Stroobant J, Heaf DP, Tyson S, Mathews DJ. Effect of inhaled azlocillin, Mistabron and combination therapy in children with cystic fibrosis. Pediatr Res 1985;19:1099.
16. MacLusky I, Levison H, Gold R, McLaughlin FJ. Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect? J Pediatr 1986;108:861-5.
17. Mukhopadhyay S. When will nebulized chemotherapy come of age? Respir Med 1994;88:245-47.
18. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
19. Lefebvre C. The Cochrane Collaboration: the role of the UK Cochrane Centre in identifying the evidence. Health Libr Rev 1994;11: 235-42.
20. Begg CB. A measure to aid in the interpretation of published clinical trials. Stat Med 1985;4:1-9.
21. Rosenfield MR, Vertrees JE, Carr J, Cipolle RJ, Uden DL, Geibank GS, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: meta-analyses of 5400 children from 33 randomized trials. J Pediatr 1994;124:555-67.
22. Chalmers TC, ed. Data analyses for clinical medicine the quantitative approach to clinical medicine. International University Press, 1988.
23. Wilson A, Henry DA. Meta-analysis: assessing the quality of published meta-analyses. Med J Austr 1992;156:173-8.
24. DerSimonian R, Laird N. Meta-analyses in clinical trials. Control Clin Trials 1986;7:177-88.
25. Bracken MB. Statistical methods for analyses of effects of treatment in overviews of randomized trials. In: Sinclair JC, Bracken MB, eds. Effective care of the newborn infant. Oxford: Oxford University Press.
26. Ashby BL, Stern DH. Aerosolized tobramycin in patients of cystic fibrosis. N Engl J Med 1993;329:1659-60.
27. Boat TF. Cystic fibrosis. In: Behrman RE, ed. Nelson Textbook of Pediatrics. Philadelphia: WB Saunders, 1992.
28. Govan JRW, Glass S. The microbiology and therapy of cystic fibrosis lung infections. Rev Med Microbiol 1990;1: 19-28.
29. Ramsey BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. J Pediatr 1994;124:177-91.
30. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991;325:533-8.
31. Shak S, Capon H, Masters SA, Baker CL. Recombinant DNase I reduces the viscosity of cystic fibrosis spatum. Proc Natl Acad Sci USA 1990;87:9188-92.
32. 1-amitrypsin treatment for cystic fibrosis. Lancet 1991;337:392-4.
33. McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al. Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992;90:1296-301.